Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

According to a new study published in Psychedelics, the answer ranges from 2.2 to 5.6 million people currently being treated ...

A new study has demonstrated the potential impact of psilocybin-assisted therapy on people with depression, if approved by ...

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental ...

'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Introduction In recent years, psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has garnered ...

Trippy: The Peril and Promise of Medicinal Psychedelics” looks at both the Indigenous use and modern research behind psychoactive substances.

Althea, a Boulder-based company, has created software they hope will become the de facto system for providers of ...

Learn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...